Pfizer-BioNTech COVID-19 Vaccine Moves Into Pivotal Trial

By Sam | August 20, 2020

Pfizer’s and BioNTech’s experimental COVID-19 vaccine BNT162b2 has been chosen for a phase 2/3 efficacy study of 9,000 participants following its success in a phase 1 trial.
Source: Drug Industry Daily

Posted in Drug Industry Daily